



BETA DRUGS LIMITED

Beta Drugs gets the DCGI nod to launch Enzalutamide 160mg for the treatment of Prostate Cancer

Beta Drugs Ltd received the Drug Controller General of India (DCGI) nod to launch Enzalutamide 160mg with the brand name ADLEAP. The company has launched this medicine with the aim to provide a much-needed treatment option for men with advanced prostate cancer.

Prostate cancer is one of the most common cancers in the male population in India. The launch of Enzalutamide 160 mg will provide ease of taking this medicine as earlier patients used to take 4 tabs of 40 mg as per the approved dosage and thus provides better patient compliance, less chance of missed dose, and ensures better efficacy.

The launch of Enzalutamide 160 mg is yet another milestone and commitment of the company to improving the lives of cancer patients through its extensive R&D capability and speed to launch its NDDS formulations. The company is focused to maintain its growth momentum through the launch of NDDS formulations and targeted therapies.

Recently, the company has also launched the much-awaited brand of Palbociclib; 'ADCILIB' which is a CDK 4/6 inhibitor indicated in Breast Cancer. In-house development of cancer drugs enables the company to bridge the unmet need of cancer patients and bring down the therapy cost for Indian patients.

Beta has a rich product pipeline and expects to launch at least 6 new molecules or NDDS formulations in FY 23-24.



CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com